Background: Circulating DNA is observed at higher concentrations in patients with lung cancer than in controls. Qualitative and quantitative analysis of circulating DNA is a promising noninvasive tool. Our aim was to prospectively study the association between the catalytic subunit of telomerase (human telomerase reverse transcriptase [hTERT]) in plasma and clinical variables and survival in a large-scale non-small cell lung cancer (NSCLC) study. Methods: Four hundred forty-six patients with stages IIIB and IV NSCLC with a median follow-up of 9.7 months (range, 0.5-45) were analyzed. Blood samples were collected before therapy start (cisplatin/docetaxel). Quantification of baseline circulating DNA was determined as the amount of free hTERT in plasma, by using real-time quantitative polymerase chain reaction. Results: Patients with hTERT Յ49.8 ng/ml (median value) had a median time to progression (TTP) of 6.3 months compared with 4.9 for hTERT more than 49.8 ng/ml (p ϭ 0.001). Overall survival (OS) was significantly higher (10.9 versus 9.3 months) at lower hTERT levels (p ϭ 0.012). When calculations were done using hTERT as continuous variable, we did not observe independent significant differences. Thus, there is an apparent discrepancy in p values when hTERT is considered as a continuous versus dichotomized variable. There was a tendency to differentiate median hTERT levels with respect to response rates (complete response ϩ partial response: 33.1 versus stable disease ϩ progressive disease: 50.7 ng/ml, p ϭ 0.12), but other clinical variables such as age, gender, performance status, stage, histology, and number of metastatic locations were not associated with hTERT. In multivariate
D
uring carcinogenesis, pathologic tissue liberates cells and cell components to the blood stream, even at early stages of the disease. [1] [2] [3] The presence of nucleic acids in blood was reported more than 30 years ago by Leon et al. 4 In the late 1990s, Kopreski et al. 5, 6 found that patients with cancer have more free DNA and RNA in the plasma or serum than healthy subjects.
The origin of this genetic material was not well established, but research up to now has confirmed a high degree of correlation between the genetic changes in the tumor and those detected in the blood, [7] [8] [9] which supports that much of the circulating DNA in the patients with cancer derives from the tumor. 10 These observations laid the foundation for the development of cell-free DNA/RNA assays for early detection of cancer and for aid in diagnosis, [11] [12] [13] although critical voices have been raised against its relevance for screening and diagnostics. 14, 15 During cancer, however, determination of plasma-or serum-free DNA may be an important prognostic factor with respect to treatment and posttherapy follow-up. 16, 17 The amount of free human telomerase reverse transcriptase (hTERT) in plasma serves as a surrogate of circulating DNA. This test is easily and noninvasively performed at any time during therapy or follow-up and requires only a limited blood sample. Nevertheless, the prognostic role has been questioned because some studies demonstrate an association with survival, 18, 19 whereas others do not. 16, 20, 21 Although the levels of circulating cell-free DNA in plasma or serum are higher in patients with lung cancer than in healthy controls, hitherto it is not resolved whether this will be of diagnostic or prognostic value. Neither has the association with clinicopathological variables such as age, gender, performance status, and stage of disease been established.
The objective of our study was to quantify the amount of the hTERT gene in cell-free DNA in plasma from a large-scale cohort of patients with non-small cell lung cancer (NSCLC) and to correlate hTERT with time to progression (TTP) and overall survival (OS), and clinicopathological variables.
MATERIALS AND METHODS

Patients
This study has been performed with blood samples from 446 patients diagnosed with advanced stage (IIIB-IV) NSCLC who were enrolled in a multicenter clinical trial of the Spanish Lung Cancer Group between February 2003 and January 2005. The patients were chemonaive at inclusion. Blood samples were obtained before the planned start of combination chemotherapy with cisplatin and docetaxel. The institutional ethical review board approved the study.
Sample Collection and DNA Isolation
All patients were sampled before chemotherapy; 10-ml samples of peripheral blood were collected in vacutainer tubes containing ethylenediaminetetraacetic acid as anticoagulant (Becton Dickson, NJ) for plasma recovery. Tubes were sent to the reference laboratory, and in less than 24 hours, ethylenediaminetetraacetic acid-blood samples were subjected to two centrifugation steps: an initial centrifugation for 10 minutes at 1100g at room temperature and a second centrifugation of the supernatants for 10 minutes at 2000g at room temperature. This plasma was stored at Ϫ80°C until further analysis.
Free DNA was extracted and purified from 400 l of plasma by using commercial DNA affinity columns (QIAampBlood Mini Kit, QIAGEN, Chatsworth, CA), following the manufacturer's recommendations, and eluted in 60 l of kit's elution buffer.
DNA Quantification in Plasma
The plasma-free DNA concentration was measured by using a previously described highly reproducible quantitative real-time polymerase chain reaction targeting the hTERT gene. 22 The two primers and the minor groove binding probe were designed to amplify specifically the gene of interest, hTERT, generating an amplicon of 98 base pairs. The sequences, synthesized by Applied Biosystems, Foster City, CA were as follows:
Forward primer: 5Ј GGC ACA CGT GGC TTT TCG-3Ј Reverse primer: 5Ј GGA GAG CAG AGG CAG AGA TCA-3Ј Minor groove binding probe: 6-FAM-5Ј TCC ACT CGA CGT CCT GA-3Ј
The reaction was done in 96-well plates with a total volume of 50 l/well, as described previously. 22 A standard curve using genomic human DNA from 50 pg to 50 ng (Applied Biosystems) was added to every amplification plate as described previously. 22 
Statistical Analysis
hTERT was analyzed as a continuous and dichotomized variable. For the dichotomized hTERT variable, the cutoff level for low and high values was set at the median. The KolgomorovSmirnov test was used to examine whether a continuous hTERT variable or its transformations followed a normal distribution. A Martingale residual analysis was run to check whether there was a linear trend between hTERT levels and survival. TTP and survival were also compared with tercils of hTERT concentrations. As hTERT values did not show a normal distribution, the comparisons were done with the nonparametric Mann-Whitney U test and Kruskal-Wallis test and the Spearman nonparametric correlation analysis. OS was calculated from the time of diagnosis and TTP from the date of treatment start. OS and TTP were calculated using the Kaplan-Meier model, and differences between groups were assessed by the log-rank test. For the multivariate analysis, we used Cox-regression analysis. All statistically significant variables from the univariate analyses were entered into the multivariate Cox analysis. A p value below 0.05 was considered statistically significant. Table 1 lists the detailed demographic and clinicopathologic characteristics of the patient population. The median age was 60 years, and 84% of the patients were men. The majority of patients was in performance stage 1 (performance stage 1: 74%, performance stage 2: 1%), 50% had adenocarcinoma, whereas 84% had stage IV NSCLC. Objective response was seen in 27% (complete response: 0.7%, partial response: 26%), whereas 73% had stable or progressive disease. TTP and OS with respect to the clinicopathological variables are also presented in Table 1 . hTERT levels ranged widely from 0.8 to 43,735 ng/ml. The median for the whole patient population was 49.8 ng/ml. The continuous hTERT variable did not follow a normal distribution even after a square root transformation. Using the Martingale residuals analysis, there was no linear trend between hTERT levels and survival, indicating that the median value as cutoff may not be justified.
RESULTS
There Table 2 ). Complete response ϩ partial response patients (33.1 ng/ml) had a significantly lower median pretreatment hTERT level, when compared with progressive disease (63.7 ng/ml, p ϭ 0.036) but not stable disease patients (45.3, p ϭ 0.52, Table 2 ). Progressive disease patients, however, had significantly higher hTERT levels than stable disease patients (p ϭ 0.035, Table 2 ).
Using dichotomized hTERT levels TTP was significantly associated with plasma hTERT. Patients with pretreatment hTERT concentration Յ49.8 ng/ml had a median TTP of 6.3 months, whereas those more than 49.8 ng/ml had median TTP of 4.9 months (p ϭ 0.001, Figure 1 ). When the material was divided according to tercils of hTERT plasma concentrations, TTP was 7.0, 4.7, and 5.3 months at first, second, and third tercils, respectively (p ϭ 0.003). Patients with hTERT Յ49.8 ng/ml had a median OS of 10.9 months, whereas those more than 49.8 ng/ml had a median OS of 9.3 months (p ϭ 0.012, Figure 2 ). According to tercils, median survival was 12.7, 9.6, and 9.8 months at first, second, and third tercils, respectively (p ϭ 0.013).
To identify significant individual prognostic markers, Cox regression analysis was performed. Using the dichoto- was not an independent prognosticator for survival (HR: 1.003, 95% CI: 0.99 -1.009, p ϭ 0.30).
DISCUSSION
In 446 patients with advanced NSCLC, we investigated the prognostic role of circulating DNA (hTERT) in plasma sampled immediately before chemotherapy start. It was observed that plasma hTERT concentrations were significantly associated with the objective response rates. Using the median value as cutoff level, we found hTERT to be a significant independent prognostic factor for both TTP and OS. Nevertheless, this could not be reproduced when the continuous hTERT variable was used.
The strength of this study is the population size, in contrast to previous studies where the investigated cohorts, in general, have numbered 100 individuals or less. The lack of healthy control samples may be a weakness but of less importance in established advanced NSCLC than for screening purposes in healthy individuals.
Although the presence of nucleic acids in blood was reported more than 30 years ago, 4 the interest were significantly aroused at the publication in 2003 by Sozzi et al. 13 ,23 of plasma hTERT data from 100 patients with NSCLC and 100 age-, sex-, and smoking-matched controls. They found significantly higher levels of free circulating DNA in patients with NSCLC than in disease-free heavy smokers and concluded that this method should be used as a new approach for early detection of lung cancer.
Research into the role of circulating DNA in established cancers has demonstrated a strong power to discriminate patients with lung cancer from those with benign lung diseases or healthy individuals. 24, 25 It has further confirmed a high degree of correlation between genetic changes in tumors and those detected in the blood. 10,15,26 -29 These findings support the hypothesis that a significant portion of the circulating DNA in patients with cancer are derived from the tumor. In a thorough review, Fleischhacker and Schmidt 10 concluded that because these free circulating DNAs are a reflexion of the physiological and pathologic processes in the human body, it makes them a very interesting target for the development of clinically useful assays.
In several nonlung malignancies such as colorectal, breast, and prostate cancer, enhanced blood DNA levels have been shown to correlate with prognosis. 29 -31 In NSCLC, there are conflicting data concerning the prognostic role of circulating hTERT in these patients. Three clinical studies, 16, 20, 21 of which the study by Sozzi et al. 16 is the largest with 84 patients with NSCLC, did now show an association with survival. Ludovini et al., 21 in 76 operable stage I to III patients with NSCLC, found that circulating DNA declined after surgery and increased at recurrence, even though it did not show any prognostic significance.
In this study, we observed that high hTERT levels were significant and independent prognosticators for TTP and OS when the dichotomized variable was used. When calculations were done using the continuous variable, we did not observe independent significant differences. Thus, there is an apparent discrepancy in p values when hTERT is considered as a continuous versus dichotomized variable. Nevertheless, increasing pretreatment plasma concentrations of hTERT was significantly associated with later reduced chemotherapy efficacy, which supports the survival differences based on hTERT cutoffs at the median value. It may be argued that the prognostic impact by plasma hTERT levels not necessarily is mediated by linear changes in hTERT levels. It should be noted that the significant associations between hTERT tercils versus both TTP and survival supports our results using the dichotomized hTERT variable.
The DNA concentrations in our study did not seem to be influenced by either pretreatment tumor characteristics or clinical variables such as age and gender. In a recent study on 46 patients with NSCLC, van der Drift et al. 32 observed that high circulating DNA levels correlated with a worse survival, consistent with our results. Also, they did not find any relationship of DNA concentration with tumor or clinical variables. In a larger NSCLC cohort of 185 patients with NSCLC, Gautschi et al. 19 reported high baseline plasma DNA to correlate with poor survival, advanced tumor stage, lactate dehydrogenase level, and leukocytes. They also observed that high DNA levels correlated to disease progression, in agreement with the independent prognostic relevance the higher dichotomized hTERT level had for TTP in our study. Fournié et al. 18 examined the plasma DNA levels in 68 hospitalized patients with lung cancer, of which 46 has NSCLC. Also in this study, high circulating DNA levels are 33 also observed poor survival at high plasma DNA concentration. Possible reasons for discrepancies regarding the prognostic impact of hTERT may be choice of patient population and sample processing. Some studies have included both small cell lung cancer and NSCLC, which differ largely in biology, treatment, and prognosis. 20, 18 Most studies have included patients with both advanced and limited surgical disease, 18, 19, 32 whereas only patients with advanced NSCLC (IIIB and IV) were included in this study. This variability may, in part, explain why there was no correlation between hTERT levels and disease stage in our study. Disparities in levels of circulating DNA between studies are primarily due to protocol differences with respect to blood sample processing, DNA extraction, and DNA quantification method. Although most researchers today use quantitative polymerase chain reaction for DNA quantification, there is still a considerable potential for further standardization of sample source, sample processing, and DNA extraction methods. 10, 23 Using a dichotomized hTERT variable, we conclude that a high baseline level of circulating hTERT is a significant independent prognosticator for poor TTP and OS in advanced NSCLC. This is supported by significant negative associations between plasma hTERT concentrations and objective response rates, and by the association between hTERT tercils versus both TTP and survival. Furthermore, the hTERT concentration was not influenced by tumor characteristics or clinical variables. hTERT analysis requires a simple, noninvasive, and affordable procedure, and it may aid in therapy evaluations and follow-up of patients with NSCLC.
